Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The megakaryocyte-to-platelet production pathway (thrombopoiesis) is a highly specialized process that generates approximately 100 billion platelets daily in humans to maintain normal platelet counts[4]. This process can be divided into three distinct phases: First, hematopoietic stem cells differentiate into megakaryocytes (MKs) in the bone marrow. During this phase, MKs undergo endomitosis (DNA replication without cell division), becoming polyploid cells with multilobed nuclei[1][6]. This phase takes several days to complete and requires specific growth factors. Second, mature MKs extend long branching processes called proplatelets into the sinusoidal blood vessels of the bone marrow. Proplatelets function as assembly lines for platelet production and are comprised of platelet-sized swellings connected by thin cytoplasmic bridges[6]. The cytoskeleton plays a crucial role in this process, with β1-tubulin being essential for proplatelet formation and elongation[1][2][6]. Mice lacking β1-tubulin produce 60% fewer platelets, and in humans, mutations in β1-tubulin result in macrothrombocytopenia[2][6]. Third, the final stage involves preplatelet maturation within the bloodstream, which is dependent on cytokine receptor-like factor 3 (CRLF3)[8]. This recently identified step completes the platelet formation process. The extracellular matrix environment significantly influences platelet production. Softer matrices promote platelet production through activation of the transient receptor potential cation channel subfamily V member 4 (TRPV4), triggering calcium influx, β1 integrin activation, and Akt phosphorylation[5]. Additionally, plasmacytoid dendritic cells (pDCs) of the immune system regulate megakaryopoiesis by releasing interferon-alpha (IFNα) in response to DNA expelled by terminal megakaryocytes, signaling bone marrow stem cells to produce more megakaryocytes[7]. Once released into circulation, human platelets survive for 7-10 days, while rodent platelets survive for 4-5 days[2]. This continuous production and turnover process is essential for maintaining hemostasis and preventing bleeding disorders.
Cytoskeletal reorganization, Endomitosis regulation, Proplatelet extension, Matrix sensing, Interferon-alpha signaling
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Megakaryocyte-to-platelet production pathway (Thrombopoiesis).